Lumateperone Adjunct Therapy Improves Depression and Sexual Function

A newly published clinical trial indicates that adjunctive treatment with lumateperone — added to existing antidepressant regimens — led to measurable improvements in both depressive symptoms and sexual function among adults with major depressive disorder who had shown inadequate response to prior therapy.

Study design and outcomes

The randomized, double-blind study enrolled 480 participants diagnosed with major depressive disorder. One group received a daily dose of 42 mg of lumateperone alongside their ongoing antidepressant treatment; the control group received placebo under identical conditions. After 43 days of intervention, the lumateperone group demonstrated statistically significant improvement across standardized assessments of depression severity and sexual functioning relative to the placebo group.

Improvements in sexual function encompassed multiple domains: libido, arousal, orgasm, and pleasure. At baseline, 82.5% of all participants reported clinically significant sexual dysfunction. By the end of the treatment period, more than one-quarter of those in the lumateperone group reported restoration of sexual function to normal levels.

Gender-specific observations

Benefits were observed in both male and female participants. Female participants showed greater magnitude of improvement in sexual outcomes, though researchers emphasized that this difference requires further investigation in larger, dedicated studies. Both men and women reported enhanced sexual pleasure and arousal.

Leadership and publication

The trial was led by Dr. Anita H. Clayton, a psychiatrist affiliated with UVA Health. Findings appeared in the journal Clinical Psychiatry.

Depression and sexual dysfunction linkage

According to the study authors, approximately 68% of individuals with major depressive disorder experience sexual dysfunction. This impairment is not attributable solely to depression itself but may also stem from adverse effects of certain antidepressants — particularly selective serotonin reuptake inhibitors (SSRIs). Such side effects can contribute to treatment discontinuation in some patients.

About lumateperone

Lumateperone is a second-generation antipsychotic approved for the treatment of schizophrenia and depressive episodes associated with bipolar I disorder. It is also indicated as adjunctive therapy to antidepressants in adults with major depressive disorder when an adequate response has not been achieved.

Clinical implications and limitations

The results suggest lumateperone may represent a viable adjunctive option for select patients with major depressive disorder who remain symptomatic on standard antidepressants — especially those prioritizing mitigation of sexual side effects. However, the findings do not indicate universal efficacy across all patients, and additional research is required to confirm and extend these observations.